Topic Archives: Gilead (GILD)

I’ve gotten a few questions about the latest Technology Profits Confidential (currently $79/yr) tease from Ray Blanco, so although it’s a few weeks old now, and started circulating right in the heat of the first coronavirus downturn in mid-March, I thought I’d take a look today. It is still a current ad, I got it […]

Please indulge Doc Gumshoe while he presents his musings on what’s going on in general in the health-care arena, and in particular, which new drugs are getting the FDA blessing and why, as well as which ones are getting the short straw.   My impressions and conclusions are in some cases only loosely based on […]

This particular bit of news leaves your friend Doc Gumshoe shaking his head in puzzlement.  To wit, in the US it is expected that there will be a substantial shortage of physicians in the upcoming years.   The American Association of Medical Colleges predicts that this shortage may reach about 122,000 physicians by the year […]

Remember Ernie Tremblay’s pitch about a “tiny South Texas lab” that was about to cure every disease using its revolutionary CD19 Cancer Vaccine technology, and ignite a bidding war following its fantastical release of exciting information on June 23? Well, it’s back. Not the stock, that’s still languishing around where it was before Tremblay got […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. You can see all of his old articles and his most recent comments on his Stock Gumshoe page.] “Keep it quiet. (Go slow.) […]

[Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trade restrictions, chooses his own topics, and his words and opinions are his own. You can see all his past articles and recent comments here.] The State of Things is a classy 1982 Wim Wenders film in which a film […]

The folks at Money Map/Money Morning have really taken the “most aggressive advertisers” mantle from the other Agora affiliates of late — we can pretty much count on a new promotional campaign from this publisher becoming the “most asked about” pitch by our readers almost instantly, whether it’s Michael Robinson or Keith Fitz-Gerald or Dr. […]

Everybody’s got to deviate from the norm.  —Rush John Galsworthy wrote that the beginning and endings of human undertakings are untidy. It was never more so than in the early days of HCV, a mere 20 years ago, when a plague first called “non-A non-B hepatitis” began vexing people, progressively scarring their livers and behaving […]

[Ed. Note: Dr. KSS is an MD and PhD who writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can see his past articles and recent comments here.] You’re probably getting it right by now—writing “2016” and not “2015.” […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can see his past articles and biography here.] “Many things you hear in this room are untrue.” (sign posted in Yale-New Haven Medical Center physician cafeteria) […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can read his past articles, latest comments, and bio here.] We love when readers write in, and most of the questions, even though privately put, are […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. You can see all of his past articles here.] “Who wants honey? As long as there’s some money?” —–“Cherub Rock,” Smashing Pumpkins, Siamese Dream (words and […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can see all of his past articles here.] “All non-denial denials. They doubt our ancestry, but they don’t say the story isn’t accurate.” —-from All the President’s […]

[Dr. KSS writes about medicine and biotech stocks for the Stock Gumshoe Irregulars. He chooses his own topics, and his words and opinions are his own. You can find his previous columns here. Enjoy!] “And stepped at once into a cooler clime.”                           […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He chooses his own topics, and his words and opinions are his own. His bio, past articles, and most recent comments can be seen here. Enjoy!] OUT of the night that covers me, Black as the Pit from pole to pole, I thank […]

[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. He choses his own topics, and his words and opinions are his own. He has agreed to our trading restrictions. Enjoy!] In his smoky baritone, singer Stuart Staples of British midlands musical act Tindersticks is bemoaning how he suspects the woman he […]

“I firmly believe that if the whole materia medica could be sunk to the bottom of the sea, it would be all the better for mankind and all the worse for the fishes.”  — Oliver Wendell Holmes, M. D., Professor of Medicine , Harvard “With all his conscience and one eye askew, So false he […]

[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. Enjoy!] It could be the premise of a tawdry unrated movie that teenage boys sneak glimpses of on Netflix when they’re home alone. […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. Enjoy!] His tidily rhyming names perhaps destined him for fame. While Jack Kerouac’s work and popularity were before my time, his cultural and literary restlessness assure him […]

[ed note: Dr. KSS is a paid contributor to Stock Gumshoe who writes about biotech stocks for (and discusses them with) the Irregulars. He chooses his own topics, and his words and opinions are his alone. Enjoy!] Greetings fellow Irregulars!  You’ve all been waiting for it….our first-ever annual ceremony in which we look back on […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own, and he has agreed to our trading restrictions.] Want to see something really cool? A hot video clip from a steamy biotech thriller? Watch this. Better yet, when you pull up the video viewing frame, […]

[Ed. Note: Dr. KSS writes about medical topics and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his thoughts and words are his own. Enjoy!] Here we are, solidly in the postmodern 21st century, “so late in the goddam day,” as one of novelist Martin Amis’s characters says, and what […]

[Ed. Note: Dr. KSS writes about medical topics and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his thoughts and words are his own. Enjoy!] Any discussion of cholesterol immediately turns Brobdingnagian, such are the extremes in question. Statins, which lower LDL cholesterol, are bombastically the best-selling drugs of all […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own.] In A History of New York, Washington Irving opens chapter VIII thus: ”In which the author and reader…fall into a very grave and instructive discourse.” This may prove to be a more unleavened column than […]

[ed note: We feature the musings of our favorite health and medicine writer, Michael Jorrin, a couple times a month, and we’ve taken the liberty of calling him “Doc Gumshoe” (he’s not a doctor). You’ll find no stock picks in his pieces, but hopefully will get plenty of insight into the medical matters he explains […]

Comments

  • Gr8Full!

    $GILD (KITE); $EDIT related - Jakobovits abruptly exits Adicet; Stanford researchers uncover mechanistic details of ALS ...

  • Gr8Full!

    $GILD - And EndPoints from John Carroll TOP STORIES Searching for HIV cure, Gilead's new 'shock and kill' combo swat...

  • Avatar

    Gilead (GILD) Said Close to Pulling Trigger on Incyte (INCY) Takeover - StreetInsider https://www.streetinsider.com/H...

  • SoGiAm

    $GILD np - Almost two years to the day since Gilead $GILD struck a deal worth up to $470 million for Phenex’s FXR agon...

  • Avatar

    Re $GLPG - this from Fierce Biotech: "Galapagos ($GLPG) CEO Onno van de Stolpe has confirmed that the standstill agreeme...

  • Avatar

    $GILD (just in): Gilead scraps a PhII/III study early as drug flops against ulcerative colitis by john carroll Sept...

  • Avatar

    $GILD just in - Gilead scraps a PhII/III study early as drug flops against ulcerative colitis by john carroll Septe...

  • Avatar

    $GILD $GLPG: Gilead tackles a big PhIII program for blockbuster hopeful filgotinib, acquired from Galapagos (GLPG) mo...

  • Dr. KSS MD PhD

    Is someone from Piper Jaffray reading us? We've said for a couple of months that Gilead ($GILD) should break up into a v...

  • Avatar

    $RGLS (long) http://tinyurl.com/z6qeum9 AbbVie ($ABBV) is touting impressive cure rates for its new daily hep C combo...

  • Avatar

    Leerink bullish on Gilead (GILD). http://blogs.barrons.com/stockstowatchtoday/2016/03/07/why-gilead-sciences-could-ga...

  • sogiam

    $ZFGN, GNFT-"Do you think anyone will give a flying faffola about NASH remedies like obeticholic acid from Intercept ($I...

  • Avatar

    Nice article on Gilead (GILD). One might wonder if Regulus (RGLS) is on their radar. http://www.fool.com/investing/gene...

  • Avatar

    Hi Everyone, I want to just take a minute to say I think the bottom is in on Gilead ($GILD). It's butting up against e...

  • Avatar

    Cramer 4 Biotech's to buy for 2016 include Gilead (GILD) and Celgene (CELG). http://www.cnbc.com/2015/12/23/cramer-bi...

  • Avatar

    Why Gilead ($GILD) and Roche ($RHHBY) Should Take a Good Look at Clovis Oncology ($CLVS) as Possible M&A Target By Mark ...

  • Avatar

    $GILD $ACHN Gilead (GILD) Rumored to be Eying Achillion (ACHN)...Again http://www.biospace.com/news_story.aspx?StoryI...

  • Avatar

    Thanks so much Doc. Gilead (GILD) is boss. Cheers,Glenn...

  • Dr. KSS, MD PhD

    Frank...I am sure it has been considered in the loftier echelons at Gilead. GILD is rapidly trying to decide whether to ...

  • sogiam

    GILD-M&A soon maybe? Gilead More Open to Deals -- Market Talk 4/3/15 4:46 PM ET (Dow Jones) -- Gilead (GILD) Chief Oper...

  • Avatar

    Interesting trade put on Gilead (GILD) today. Investor could lose up to 1.2 million if GILD does not clear 111.50 in two...

  • Avatar

    Gilead (GILD) warns after patient dies on its HEP C drug Harvoni or Sovaldi with the heart treatment amiodarone.Nine pa...

  • Avatar

    Great article. Noticed the recent link between Arrowhead (ARWR) and Gilead (GILD). In your opinion, could a combination...

  • Avatar

    More good news on Gilead (GILD), posted on Barron's blog today: Gilead Sciences: Another Big Jump in Hep-C Prescription...

  • Avatar

    John Carroll (Fierce) reported this morning that, in a surprise move, Bristol-Myers drops U.S. approval plans for hep C ...

  • Avatar

    Currently my two favorite big upside safer small biotechs are Sinovac (SVA) and Cellceutix (CTIX). Two much safer big b...

  • Dr. KSS, MD PhD

    Gilead (GILD) earnings beat: $ 2.36 EPS versus mean analyst estimate of $1.73 EPS. Blow out! 3.4B Sovaldi sale...

  • Avatar

    Check out this very positive Barron's article on Gilead (GILD): http://www.forbes.com/sites/kenkam/2014/06/06/how-gilea...

  • Dr. KSS, MD PhD

    A digression to remind people that Gilead (GILD), large cap biotech or not, remains a screaming buy in my opinion. For t...

  • frank archambeau

    Siva; I recently noticed that Gilead GILD is a sponsor & advertiser of Nascar pushing their hepC product. Unlikely pairi...

  • karmaswimswami

    To Winston Faust: One thing I think everybody here should do is use whatever software or site you use to track stocks, a...

  • frank archambeau

    DR KSS I well may have missed comments if you have already covered but is something going on at Gilead GILD. I boug...

  • Avatar

    Gilead (GILD)...

  • Avatar

    That one is Gilead (GILD), though the stock recently tanked and is crawling back from the dead!...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch